Email:
global@GCP-ClinPlus.com
Exciting news for global biopharma companies! China's NMPA is proposing to slash clinical trial review times from 60 to just 30 working days for novel medicines – a game-changing development that reinforces China's position as a premier destination for international clinical research.
Why This Matters for Your Clinical Strategy:
Faster Time-to-Market: Cut your review waiting time in half
Enhanced Predictability: Streamlined timelines for better planning
Global Standards: China's continued alignment with ICH guidelines
This proposal represents the latest milestone in China's remarkable regulatory transformation. From requiring 6+ months for IND approvals just a decade ago, to joining ICH in 2017, to implementing the current 60-day policy in 2018 – China has consistently reduced barriers for international clinical trials.
The Bottom Line: China's 1.4 billion population, world-class medical infrastructure, and now even faster regulatory pathways create an unparalleled opportunity for global biopharma companies to accelerate their clinical development programs.
Ready to explore how these regulatory advances can benefit your clinical trial strategy in China? Our team specializes in navigating China's evolving regulatory landscape to help international companies launch successful clinical programs. Contact us now at global@gcp-clinplus.com or +1 (609) 255-3581